Related by context. All words. (Click for frequent words.) 77 pivotal Phase III 76 Phase III clinical 74 Phase 2b clinical 74 phase IIa clinical 72 pivotal Phase 72 Phase 2b study 72 Phase IIb 72 Phase Ib 72 Phase III 71 Phase 2b trial 71 phase IIb 71 Phase 1b clinical 71 Phase IIb trial 71 phase IIb clinical 71 Phase 2a clinical 71 Phase IIa trial 70 Phase 2b 70 SUCCEED trial 70 Phase IIIb clinical 70 Phase IIb clinical 70 phase IIa 70 confirmatory Phase III 70 Phase IIa clinical 69 multicenter Phase 69 Phase Ib II 69 Phase 2a 69 Phase 2a trial 69 Phase 1b trial 68 Phase 1b 68 confirmatory Phase 3 68 Phase III clinical trials 68 phase Ib 68 randomized Phase IIb 67 dose escalation trial 67 COMFORT II 67 Phase Ib clinical 67 dose escalation Phase 67 placebo controlled Phase III 67 Phase IIa 67 oral ridaforolimus 67 Phase #b/#a 67 registrational 67 placebo controlled Phase 67 APEX PD 67 phase 2a 66 LibiGel Phase III 66 phase IIb trial 66 Phase IIIb 66 Phase II 66 Investigational Device Exemption IDE 66 Phase III trials 66 registrational trial 66 multicenter clinical 65 ADVANCE PD 65 randomized controlled Phase 65 ENDEAVOR IV 65 randomized Phase 65 Augment Injectable 65 BRIM2 65 Phase IIb trials 65 dose escalation clinical 65 Phase Ib study 64 phase IIIb 64 rALLy clinical trial 64 Phase 2b kidney transplant 64 Phase III placebo controlled 64 Phase #b/#a clinical 64 Phase IIb clinical trials 64 multicenter Phase II 64 MAA submission 64 TG MV 64 placebo controlled clinical 64 IIa trial 64 lorcaserin Phase 64 randomized Phase III 64 prospective multicenter 64 Pivotal Phase III 64 Phase 1a 64 multicenter prospective 64 Amrubicin 63 Phase IIB 63 Dacogen injection 63 Phase III randomized 63 BLA filing 63 ongoing Phase 1b 63 pivotal bioequivalence 63 PFO migraine 63 Phase IIa trials 63 clinical trial 63 Marketing Authorization Application MAA 63 Phase Ib clinical trials 63 phase Ib clinical 63 Phase #/#a 63 Phase IIb kidney transplant 63 dose escalation study 63 phase IIb study 63 Phase III psoriasis 62 Phase Ia 62 GEM OS1 62 Pivotal Trial 62 MIST II 62 BRIM3 62 viral kinetic 62 Proxinium TM 62 Urocidin 62 lorvotuzumab mertansine 62 COSIRA trial 62 blinded randomized placebo controlled 62 Phase IIb III 62 Phase III confirmatory 62 NO# [002] 62 Phase 2b clinical trials 62 LUMINATE 62 masked placebo controlled 62 forodesine 62 Zenvia ™ 62 Phase III metastatic melanoma 62 GetGoal Phase III 62 Phase 2b randomized 62 Luveniq 62 randomized controlled multicenter 62 Phase III randomized controlled 62 pharmacokinetic PK study 62 alvimopan 61 IIa clinical trial 61 multicentre randomized 61 label multicenter 61 CRMD# 61 unblinded 61 CUSTOM III 61 Microplasmin 61 Phase Ib IIa 61 PANVAC VF 61 initiate Phase IIb 61 peginesatide 61 INCB# [002] 61 BLA submission 61 ENDEAVOR III 61 PREOS R 61 zalutumumab 61 multiple ascending dose 61 CLARITY study 61 Phase 1a clinical 61 PDX pralatrexate 61 Zenvia Phase III 61 Phase IIIb study 61 ruxolitinib 61 prospective multicenter randomized 61 dermaPACE ™ 61 oral deforolimus 61 placebo controlled randomized 61 Phase III HEAT 61 OvaRex ® MAb 61 HuMax EGFr 61 BST CarGel R 61 TAXUS Element Stent System 61 Diabetic Macular Edema 61 metastatic sarcomas 61 PrevOnco ™ 61 ENRICH trial 61 deforolimus 61 NEO3 61 ABSORB trial 61 brivaracetam 61 Phase III multicenter 61 EOquin TM 61 NDA submission 61 relapsed refractory multiple myeloma 61 EDEMA3 61 dose escalation 61 CHAMPION PCI 61 XIENCE V Stent System 60 EchoCRT 60 ThermoDox R 60 PROPEL trial 60 Ketotransdel 60 FOLOTYN ® 60 dalbavancin 60 Aryplase 60 MONOVISC 60 multicenter Phase III 60 Phase III Clinical Trial 60 fidaxomicin Phase 3 60 Omigard 60 Allovectin 7 60 label dose escalation 60 omacetaxine mepesuccinate 60 PREOS 60 NP2 Enkephalin 60 OncoVEX GM CSF 60 obatoclax 60 pain palliation 60 octreotide implant 60 sNDA submission 60 NEBIDO 60 Zerenex 60 PRECISE trial 60 multicenter phase 60 axitinib 60 Cloretazine ® 60 IL# PE#QQR 60 Sorafenib HCC Assessment 60 EVEREST II 60 ThermoDox ® 60 multicenter randomized controlled 60 placebo controlled 60 Phase III TRIST 60 T Pred 60 SNT MC# 60 single ascending dose 60 Fodosine 60 APPRAISE 60 GALNS 60 rALLy trial 60 Premarket Approval PMA 60 MERLIN TIMI 60 EmbraceAC 60 Vascular Wrap TM 60 Alzhemed TM 60 acyclovir Lauriad R 60 PRECISE 60 randomized multicenter 60 Bronchitol 60 satraplatin Phase 59 ELACYT 59 randomized controlled 59 Phase 1b dose escalation 59 JAK inhibitor 59 Cloretazine R VNP#M 59 CoFactor 59 ABSORB clinical 59 randomized Phase 2b 59 AIR CF1 59 Fibrillex TM 59 DSMB 59 TAXUS Element Paclitaxel Eluting 59 miconazole Lauriad R 59 ATryn R 59 TASKi2 59 Augment Bone Graft 59 alvespimycin 59 Marketing Authorization Application 59 multicenter randomized placebo controlled 59 IMPACT IMmunotherapy 59 huC# DM4 59 registrational Phase 59 Fibrin Pad 59 opioid induced bowel dysfunction 59 tesmilifene 59 Fx #A 59 dosing cohorts 59 Phase III Pivotal 59 INCB# [001] 59 granted Ortec 59 multicenter randomized Phase 59 European Sepsis Trial 59 Corlux 59 Allovectin 7 ® 59 Ophena 59 AzaSite Plus 59 tanespimycin 59 EFAPROXYN 59 OPT CHF 59 unblinding 59 palifosfamide 59 multicenter 59 ENDEAVOR IV clinical 59 PRESEPT 59 clinical pharmacology studies 59 Panzem R NCD 59 Biologics License Application BLA 59 ZYBRESTAT 59 SPIRIT FIRST 59 LUX Lung 59 Anturol 59 double blinded placebo 59 Phenoptin 59 OLpur TM H2H 59 randomized placebo controlled 59 dermaPACE 59 ToGA 59 AVADO 59 evaluating REVLIMID 59 IIa clinical 59 Iluvien ® 59 sunitinib malate 59 budesonide foam 59 Exherin TM 59 evaluating Actimmune 59 multicentre 59 Drug Eluting Stent System 59 huN# DM1 59 ZYBRESTAT fosbretabulin 59 teduglutide 59 nab paclitaxel 59 prospective randomized controlled 59 Phase III Clinical Trials 59 investigational pan BCR 59 Nasdaq PGNX today 59 prospective randomized 58 metastatic HRPC 58 Board DSMB 58 TAXUS ATLAS 58 fosbretabulin 58 AP# [003] 58 glufosfamide 58 PRECiSE 58 VNP#M 58 Dual Opioid 58 TELCYTA 58 unblind 58 Combination REOLYSIN R 58 Tarceva TM 58 Cellegesic 58 EOquin 58 IND submission 58 REVIVE Diabetes 58 Cladribine Tablets 58 BEMA TM Fentanyl 58 dose cohort 58 Vicinium TM 58 randomized clinical 58 ORBIT II 58 IMA# 58 Loramyc R 58 apaziquone 58 StemEx 58 ozarelix 58 LUVENIQ 58 assessing T DM1 58 Plicera 58 Pivotal Phase 58 brentuximab vedotin SGN 58 aflibercept 58 GEM OS2 58 SPIRIT III 58 blind randomized placebo 58 diabetic neuropathic pain 58 evaluating tivozanib 58 FOSRENOL 58 Pivotal Study 58 ofatumumab 58 randomized controlled clinical 58 phase IIb III 58 RSD# oral 58 FIRMAGON R 58 QLT# 58 ofatumumab HuMax CD# 58 Entereg R 58 paclitaxel poliglumex 58 phase III ACCLAIM 58 OZURDEX ® 58 Aplidin 58 virus HCV protease inhibitor 58 Pirfenidone 58 SPIRIT IV 58 afamelanotide 58 MIVI III 58 tolevamer 58 vosaroxin 58 Trobalt 58 relapsed multiple myeloma 58 Medidur TM FA 58 Soliris TM eculizumab 58 ELIQUIS 58 initiate Phase 58 CEQ# 58 confirmatory clinical 58 SYMMETRY trial 58 Restanza 58 ENDEAVOR II 58 ANCHOR trial 58 Chemophase 58 Pivotal Clinical Trial 58 Phase 1b clinical trials 58 Genasense ® 58 docetaxel Taxotere R 58 photoprotective drug 58 CALGB 58 Phase #b/#a trial 58 ongoing Phase IIIb 58 Raptiva R 58 ACCEDE 58 thorough QT 58 ARIKACE 58 DAPT Study 58 Ceplene 58 PROVENGE ® 58 crizotinib PF # 58 enzastaurin 58 carboplatin paclitaxel 58 ARDIS 58 mertansine 58 elacytarabine 58 multicenter placebo controlled 58 refractory metastatic colorectal cancer 58 IRX 2 57 neratinib 57 selective androgen receptor modulator 57 MEND CABG 57 treatment naïve genotype 57 clinical trials 57 initiated Phase Ib 57 Onrigin 57 HuMax CD4 57 RE LY 57 StemEx R 57 PRECISE Trial 57 TMC# C# 57 evaluating nimotuzumab 57 RhuDex ® 57 ORENCIA R 57 confirmatory Phase 57 CB2 selective receptor agonist 57 controlled multicenter 57 dirucotide 57 recurrent malignant glioma 57 QNEXA ® 57 IIb clinical trial 57 ataluren 57 REVLIMID lenalidomide 57 NVA# 57 Fast Track designation 57 UPLYSO 57 IMPACT DCM trial 57 unresectable malignant mesothelioma UMM 57 NCCTG 57 Plenaxis TM 57 TRISENOX 57 Iluvien 57 oral calcitonin 57 MVax 57 ORENCIA ® 57 Onalta ™ 57 Phase 2b Clinical Trial 57 luliconazole 57 Amigal 57 PERSEUS 57 CLIRS trial 57 carfilzomib 57 dose cohorts 57 RG# [001] 57 ADVEXIN 57 dermaPACE TM 57 LBH# 57 active comparator 57 EDEMA4 57 CALGB # [002] 57 Initiate Phase 57 azficel T 57 Prostate AdenoCarcinoma Treatment 57 PROMUS Element Stent System 57 Icatibant 57 Dyloject TM 57 sapacitabine 57 Cimzia ® certolizumab pegol 57 catheter occlusion 57 pharmacokinetics PK 57 initiate Phase 1b 57 II Clinical Trial 57 CLL8 57 Raptiva ® 57 BCIRG 57 Phase Ib IIa clinical 57 ATL# [001] 57 SEPET TM 57 Evoltra 57 Phase IIB clinical 57 elotuzumab 57 mGluR5 negative 57 Glybera R 57 satraplatin 57 OvaRex R 57 PROVENGE sipuleucel T 57 MGCD# [001] 57 AEG# 57 relapsing remitting MS RRMS 57 LibiGel BioSante 57 Proellex TM 57 BENLYSTA 57 oral rivaroxaban 57 IMGN# 57 GAMMAGARD 57 Targretin capsules 57 Application BLA 57 Troxatyl 57 Reolysin 57 isavuconazole 57 Ophena TM 57 cangrelor 57 Phase lll 57 trastuzumab emtansine T DM1 57 Initiated Phase 57 trastuzumab DM1 T DM1 57 PRIMO CABG 57 AZILECT R 57 TASQ 57 multicenter randomized clinical 57 dosing cohort 57 randomized double 57 Gabapentin GR 57 PHX# 57 Tanespimycin 57 BrachySil TM 57 TEMODAL 57 Allovectin 7 R 57 LibiGel testosterone gel 57 prospective observational 57 bazedoxifene 57 VITAL Trial 57 Genasense ® oblimersen 57 perifosine 57 pharmacokinetic PK 57 Phase 2b monotherapy 57 ponatinib 57 FAME Study 57 afatinib 57 Initiate Phase II 57 HGS# 57 tramiprosate Alzhemed TM 57 EURIDIS 57 forodesine HCl 57 ZEVALIN 57 Aflibercept 57 PDE4 inhibitor 57 CONBRIZA 57 TORISEL 57 ILUVIEN ® 57 PEG PAL 57 relapsing multiple sclerosis 57 LibiGel ® 57 GOUT 57 MIRCERA 57 Randomized Phase II 57 CLIRS 57 Azedra TM 57 exemption IDE 57 AQ4N 57 multicenter randomized 57 oxymorphone ER 57 lymphoma CTCL 57 pertuzumab 57 Asentar 57 liver resection surgeries 57 FOLFOX6 chemotherapy regimen 57 vidofludimus 57 talactoferrin 57 Torisel 57 Traficet EN 56 Phase IIb Clinical Trial 56 bicifadine 56 compound INCB# 56 IND enabling 56 MEK inhibitor RDEA# 56 Phase IIa clinical trials 56 ixabepilone 56 eniluracil 56 Civacir 56 double blind placebo 56 Phase IIb Trial 56 Locteron ® 56 Marqibo 56 ACTEMRA TM 56 cutaneous T cell 56 initiate Phase 2b 56 Capesaris 56 antibody MAb 56 BR.# 56 Anturol TM 56 TAXUS Liberte 56 double blinded randomized 56 Clolar ® 56 QNEXA 56 Phase 56 IMPACT DCM 56 PS# DARA 56 PSMA ADC 56 drug eluting stent DES 56 BAY #-# 56 Phase #/#a trial 56 Multaq R 56 induced macular edema 56 ATryn ® 56 GLP toxicology studies 56 Phase III registrational 56 interferon beta 1b 56 GRAVITAS trial 56 budesonide MMX Phase III 56 ALN VSP Phase 56 NEVO ™ 56 SinuNase TM 56 Loramyc ® 56 NEVO TM 56 Oncoscience AG 56 Phase III ADT 56 UVIDEM 56 Ventavis 56 MAGE A3 ASCI 56 ZYBRESTAT TM 56 DASISION 56 candidate brentuximab vedotin 56 IMC A# 56 Amigal TM 56 denosumab oncology 56 severe hypercholesterolemia 56 TRO# 56 Tavocept 56 Biologics License Application 56 FIRAZYR 56 YONDELIS 56 subcutaneous formulation 56 CCR5 antagonist 56 Alocrest 56 relapsing remitting multiple sclerosis 56 farletuzumab 56 oral prodrug 56 lintuzumab SGN 56 oral Xeloda 56 ganetespib 56 MoxDuo IR 56 Archexin 56 Ixempra 56 dose dose escalation 56 EMPOWER ™ 56 THALOMID 56 Marketing Authorisation Application 56 STELARA 56 LymphoStat B 56 MEND CABG II 56 Endeavor drug eluting 56 Arzerra TM 56 systemic anaplastic large 56 ocrelizumab 56 mSEPT9 56 label multicenter Phase 56 refractory Hodgkin lymphoma 56 interferon gamma 1b 56 amifampridine phosphate 56 Virulizin R 56 NOXAFIL 56 RE SURGE 56 Phase Ia Ib 56 blind randomized 56 T DM1 56 lintuzumab 56 drug eluting coronary stent 56 multicenter randomized double 56 MOZOBIL 56 LEUKINE 56 INSPIRE Trial Phase III 56 systemic ALCL 56 cell lymphoma CTCL 56 reslizumab 56 microplasmin 56 ACCLAIM II 56 VESTAsync 56 Phase III ALLEGRO 56 platinum refractory 56 NEVO 56 FORTIS M trial 56 AZX# 56 eculizumab 56 ospemifene 56 BioMatrix TM 56 methylnaltrexone bromide 56 AZILECT ® 56 AZX# Phase 56 anticancer compound 56 phase III SIMPADICO 56 Voraxaze 56 dextromethorphan quinidine 56 rNAPc2 56 fostamatinib 56 PEARL SC 56 Lodotra TM 56 Multicenter 56 romidepsin 56 Oglemilast 56 blind multicenter 56 cannabinor 56 PARTNER Trial 56 BioSTAR R 56 biliary tract cancer 56 OLpur TM MD 56 multicentre randomized double 56 PF # [002] 56 Levacor 56 TheraCIM 56 RE LY ® 56 miconazole Lauriad ® 56 LEVADEX ™ 56 evaluating carfilzomib 56 Treanda 56 Diamyd R 56 Proxinium 56 blinded placebo controlled 56 Zelrix 56 teriflunomide 56 STRIDE PD 56 Phase 2a clinical trials 56 Betaferon ® 56 fully bioabsorbable 56 Androxal TM 56 ICA # 56 Personalized Immunotherapy 56 confirmatory pivotal 56 Myocet 56 PIX# trial 56 StaphVAX 56 ZEVALIN ® 56 receptor tyrosine kinase inhibitor 56 Multikine ® 56 acyclovir Lauriad ® 56 maribavir 56 ADVEXIN clinical 56 CR# vcMMAE 56 Feasibility Trial 56 TACI Ig 56 recurrent metastatic 56 Anturol ® 56 Investigational Device Exemption 56 GATTEX ® 56 ezogabine 56 albinterferon alfa 2b 56 clinicaltrials 56 Diamyd ® 56 incyclinide 56 prospective randomized multicenter 56 PMA submission 56 riociguat 56 pediatric glioma 56 evaluating T DM1 56 BCX# 55 PEP# [003] 55 lexidronam injection 55 Xanafide 55 Omigard TM 55 picoplatin 55 FlutiformTM 55 bardoxolone 55 POSIDUR TM 55 Eluting Coronary Stent System 55 elagolix 55 ICON7 55 voclosporin 55 Aurexis 55 NSABP 55 histamine dihydrochloride 55 Phase III ThermoDox 55 Inhalation Solution 55 hoFH 55 Biologic License Application BLA 55 ILLUMINATE 55 multicenter study 55 Diabetic Macular Edema DME 55 Liberte TM 55 ARCOXIA 55 unique alkylating agent 55 MEPACT 55 PROMACTA 55 Evoltra ® 55 SinuNase 55 Urocortin 2 55 NADiA ProsVue 55 lomitapide 55 pharmacokinetic studies 55 PREVAIL 55 delivers fluocinolone acetonide FA 55 TOLAMBA 55 valopicitabine 55 CHARM Added 55 REOLYSIN ® 55 Evoltra TM 55 TAXUS TM 55 Oracea TM 55 CIP ISOTRETINOIN 55 oral methylnaltrexone 55 Lymphoseek ® 55 Cloretazine 55 Dyloject 55 balsalazide tablet 55 orBec 55 HORIZONS AMI trial 55 Quinamed 55 Ranolazine 55 Alpharadin 55 Neovasc Reducer 55 Azixa 55 FOLOTYN 55 Phase III Trial 55 New Drug Application 55 Azedra 55 MabCampath 55 LIALDA 55 Canvaxin 55 initiate Phase Ib 55 M Vax 55 Virulizin ® 55 metastatic hormone refractory 55 Lucanix R 55 YONDELIS R 55 Catena ® 55 TAXUS IV 55 Tyrima 55 Rhucin ® 55 sodium Injection 55 RSR# 55 de novo kidney transplant 55 generation purine nucleoside 55 resminostat 55 APEX AMI trial 55 velaglucerase alfa 55 metastatic castrate resistant 55 PROTECT AF 55 HCV protease inhibitor 55 tamibarotene 55 L BLP# 55 ASCEND HF 55 MyVax personalized immunotherapy 55 Taxotere ® 55 SUTENT 55 belinostat 55 SUTENT ® 55 Stedivaze 55 Ozarelix 55 Loramyc 55 torezolid phosphate 55 APTIVUS 55 sorafenib tablets 55 PRX # 55 Valtropin 55 ACOMPLIA R 55 investigational humanized monoclonal antibody 55 PreCISe 55 pazopanib 55 CURE AF 55 candidates bavituximab 55 PreCISe study 55 Angiox ® 55 Kamada AAT 55 Vectibix panitumumab 55 Simulect 55 RESOLUTE clinical 55 TroVax 55 Laquinimod 55 clofarabine 55 rilonacept 55 YERVOY 55 TYKERB 55 Prospective Randomized 55 CAMMS# 55 Nexavar ® 55 sevelamer carbonate 55 3 registrational trial 55 ProLindac TM 55 IMC #B 55 APF# Phase 55 INC# 55 RDEA# 55 FRDA 55 investigational drug 55 investigational antiplatelet agent 55 PRoFESS 55 HspE7 55 Qutenza TM 55 prucalopride 55 Phase III Psoriasis 55 mifamurtide 55 Zemplar Capsules 55 daclizumab 55 ACAPODENE 55 Keppra ® levetiracetam 55 TBC# 55 dacetuzumab SGN 55 NUVIGIL 55 Darusentan 55 PSN# [002] 55 PHASE III 55 indibulin 55 DIRECT Trial 55 midstage trials 55 PROMUS Element Stent 55 pharmacokinetic pharmacodynamic 55 inhaled liposomal ciprofloxacin 55 ANTEGREN 55 Rhucin 55 IMPACT DCM clinical 55 TAXUS VI 55 fidaxomicin 55 AIR CF2 55 Troxatyl TM 55 Shigamabs ® 55 recurrent glioblastoma multiforme 55 BLOOM DM 55 Ceplene R 55 evaluating Vectibix 55 celgosivir 55 JZP 55 Mepact 55 thymalfasin 55 ACTEMRA 55 ecallantide 55 GATTEX TM 55 pralatrexate injection 55 Fodosine TM 55 TEMSO 55 CAPHOSOL R 55 evaluating satraplatin 55 OMP designation 55 PLX PAD 55 ISTODAX ® 55 BRILINTA 55 AMITIZA R 55 TLK# 55 EXPAREL ™ 55 randomized blinded 55 bile duct tumor 55 cardio renal 55 pseudobulbar affect PBA 55 OPAXIO 55 ONTARGET 55 randomized multicenter trial 55 candidates Dyloject TM 55 Clevudine 55 TASKi3 55 LCP AtorFen 55 mipomersen 55 Vernakalant 55 null responder HCV 55 HGS ETR1 55 Xibrom TM 55 HER2 positive metastatic breast 55 Vascular Wrap 55 Entereg TM 55 docetaxel Taxotere ® 55 overactive bladder AA# 55 VESTASYNC 55 velafermin 55 Mipomersen 55 PEG SN# 55 methylnaltrexone 55 Endovascular Valve Edge 55 histone deacetylase HDAC inhibitor 55 Phase III VISTA 55 dose escalation phase 55 tivozanib 55 HORIZONS AMI 55 REPEL CV 55 Panzem R 55 midstage clinical 55 RELOVAIR ™ 55 MYCAMINE 55 COSTAR II 55 SABCS 55 Maximum Tolerated Dose MTD 55 BioNumerik 55 PD LID 55 cystinosis patients 55 dirucotide MBP# 55 HepeX B TM 54 miconazole Lauriad 54 Zingo TM 54 DAVANAT 54 Ceflatonin R 54 oral FTY# 54 ascending dose 54 Tarvacin TM 54 Omacetaxine 54 Cethrin 54 Ereska 54 pitavastatin 54 Cotara R 54 ridaforolimus 54 BrachySil 54 ONCONASE R 54 CardioFit 54 controlled multicenter Phase 54 acute peripheral arterial 54 ProLindac 54 multicenter multinational 54 CRLX# 54 landmark ATHENA 54 OMS# 54 arzoxifene 54 adecatumumab 54 investigational compound 54 randomized multicenter Phase III 54 GATTEX 54 vernakalant oral 54 icatibant 54 Elagolix 54 Teysuno 54 Junovan TM 54 PRTX 54 lubiprostone 54 TRANSFORMS 54 Xyrem ® 54 Q#IR 54 Hedgehog antagonist